Sriram S., Arul Amutha Elizabeth, Akila L
Sriram S.1*, Arul Amutha Elizabeth2, Akila L3
1Postgraduate, Department of Pharmacology, Sree Balaji Medical College and Hospital, Chennai.
2Professor and HOD, Department of Pharmacology, Sree Balaji Medical College and Hospital, Chennai.
3Professor, Department of Pharmacology, Sree Balaji Medical College and Hospital, Chennai.
Volume - 13,
Issue - 12,
Year - 2020
Background: Millions of people worldwide are affected by diabetes and this disease has increased morbidity, compromised quality of life and also increased mortality. According to World Health Organization (WHO), India had 69.2 million people living with diabetes in 2015. Sodium glucose co-transporter 2 (SGLT2) inhibitors, a new class of oral anti-diabetic drugs, have garnered considerable attention in the recent past. In the recent AACE and ADA guidelines, SGLT2 inhibitors have moved up the ladder next only to Metformin and GLP-1 Receptor Agonists, in management of Diabetes mellitus. Methods: Prices of various Gliflozins (SGLT2 Inhibitors) marketed by different companies were obtained from pharmacies in the locality. The variation between highest and lowest price of the different molecules manufactured by various pharmaceutical companies and percentage variation in price for ten tablets was calculated. Results: 358.8% is the cost difference between the most expensive and least expensive gliflozin brand available in India. Conclusion: Cost of various molecules available in the market has to be known by the physician and kept in mind before prescribing the particular drug. Benefit to the patient and better drug compliance can be ensured by opting cheaper alternatives without compromising quality of the drug. Wherever needed, dose escalations or combination drugs should be initiated before opting Expensive drugs.
Cite this article:
Sriram S., Arul Amutha Elizabeth, Akila L. Cost Analysis of SGLT2 Inhibitors in patients with type 2 Diabetes in India. Research J. Pharm. and Tech. 2020; 13(12):5861-5865. doi: 10.5958/0974-360X.2020.01021.5
1. World Health Organisation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva, Switzerland; 2006.
2. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37Suppl 1: S81-90
4. International Diabetes Federation. IDF diabetes Atlas.7 thed. Brussels: International Diabetes Federation;2016.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412.
6. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281: 2005-2012.
7. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653.
8. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, et al. (2006) Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29: 1963-1972.
9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577-1596.
10. Papazafiropoulou AK, Kardara MS, Pappas SI (2011) Challenges for the treatment of diabetes mellitus. Recent Pat Endocr Metab Immune Drug Discov 5: 203-209.
11. Washburn WN (2009) Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 52: 1785-1794.
12. Idris I, Donnelly R (2009) Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 11: 79-88.
13. Abdul-Ghani MA, Norton L, DeFronzo RA (2012) Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 12:230- 238.
14. Akila L, Rani RJ. Cost analysis of different brands of antianginal drugs available in India. Int J Basic Clin Pharmacol 2015; 4:860-3.
15. Polli JW, Humphreys JE, Harmon KA, Webster LO, Reese MJ, et al. (2012) Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes. J Diabetes Metab 3:200. doi:10.4172/2155-6156.1000200
16. Vernon JA, Golec JH, Hughen WK. The economics of pharmaceutical price regulation and importation: refocusing the debate. Am J Law Med. 2006;32(2-3):175-92.
17. Rajadnya VA, Dhavalshankh AG. Cost comparisons of seven leading brands of the Hypolipidemic drug, Rosuvastatin available in an India city. Int J Basic Clin Pharmacol 2019;8:1514-7.